ES2039209T3 - Agente farmaceutico que contiene un factor de estimulacion de colonias granulociticas humano. - Google Patents

Agente farmaceutico que contiene un factor de estimulacion de colonias granulociticas humano.

Info

Publication number
ES2039209T3
ES2039209T3 ES198787100811T ES87100811T ES2039209T3 ES 2039209 T3 ES2039209 T3 ES 2039209T3 ES 198787100811 T ES198787100811 T ES 198787100811T ES 87100811 T ES87100811 T ES 87100811T ES 2039209 T3 ES2039209 T3 ES 2039209T3
Authority
ES
Spain
Prior art keywords
human
pharmaceutical agent
agent containing
stimulation factor
colony stimulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787100811T
Other languages
English (en)
Other versions
ES2039209T5 (es
Inventor
Masahiko Tamura
Kunihiro Hattori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11745897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2039209(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2039209T3 publication Critical patent/ES2039209T3/es
Publication of ES2039209T5 publication Critical patent/ES2039209T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE DESCRIBE UN AGENTE FARMACEUTICO QUE TIENE UNA COLONIA DE GRANULOCITOS HUMANOS, QUE ESTIMULAN EL FACTOR (G-CSF HUMANO) COMO INGREDIENTE ACTIVO Y QUE ES EFICAZ PARA PROMOVER LA RECUPERACION DE LA CAPACIDAD HOMOPOYETICA DE PACIENTES CON TRASTORNOS HOMOPOYETICOS, QUE HAN RECIBIDO EL TRATAMIENTO DE TRANSPLANTE DE MEDULA DE HUESO. G-CSFS HUMANOS QUE SON ADECUADOS PARA UTILIZAR EN UN AGENTE FARMACEUTICO DE LA PRESENTE INVENCION INCLUYEN LOS OBTENIDOS POR SEPARACION A PARTIR DE LIQUIDO SOBRENADANTE DEL CULTIVO DE CELULAS PRODUCTORAS DE G-CSF HUMANO Y POLIPEPTIDOS O GLICOPROTEINAS QUE TIENEN ACTIVIDAD G-CSF, QUE SE OBTIENEN MEDIANTE TECNOLOGIA RECOMBINANTE DE DNA.
ES87100811T 1986-01-22 1987-01-21 Compuesto farmaceutico que promueve el restablecimiento de la capacidad hemopoyetica. Expired - Lifetime ES2039209T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1028086 1986-01-22

Publications (2)

Publication Number Publication Date
ES2039209T3 true ES2039209T3 (es) 1993-09-16
ES2039209T5 ES2039209T5 (es) 1996-07-16

Family

ID=11745897

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87100811T Expired - Lifetime ES2039209T5 (es) 1986-01-22 1987-01-21 Compuesto farmaceutico que promueve el restablecimiento de la capacidad hemopoyetica.

Country Status (5)

Country Link
EP (1) EP0230980B2 (es)
AT (1) ATE65403T1 (es)
CA (1) CA1297004C (es)
DE (1) DE3771509D1 (es)
ES (1) ES2039209T5 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
WO1992011022A1 (fr) * 1990-12-25 1992-07-09 Kyowa Hakko Kogyo Co., Ltd. Preparation pharmaceutique destinee a une administration par voie nasale
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
EP0953354A4 (en) 1996-08-13 2002-10-23 Fujisawa Pharmaceutical Co HEMATOPOIETIC STEM CELLS PROLIFERING ACTIVE SUBSTANCES
DE19860801A1 (de) * 1998-12-30 2000-07-06 Rhein Biotech Proz & Prod Gmbh Rekombinanter Wachstumsfaktor mit der biologischen Aktivität eines G-CSF (Granulocyte Colony Stimulating Factor)
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
KR100961859B1 (ko) 2001-07-11 2010-06-09 맥시겐 홀딩스 엘티디 지-씨에스에프 접합체
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
EP2426139B1 (en) 2002-08-27 2014-10-01 Biokine Therapeutics Ltd. CXCR4 antagonist and use thereof
KR20080027291A (ko) 2005-06-01 2008-03-26 맥시겐 홀딩스 엘티디 피이지화된 지-씨에스에프 폴리펩타이드 및 그 제조방법
EP3011961B1 (en) 2006-12-21 2020-11-11 Biokine Therapeutics LTD. 4f-benzoyl-tn14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation
EP2396023A2 (en) 2009-02-11 2011-12-21 Yeda Research and Development Co. Ltd. Short beta-defensin-derived peptides
US9427456B2 (en) 2009-06-14 2016-08-30 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
DE102014001250C5 (de) 2014-02-03 2021-07-29 Carl Freudenberg Kg Fensterwischer
MX2017016844A (es) 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
CA3014530A1 (en) 2016-02-23 2017-08-31 Biolinerx Ltd. Methods of treating acute myeloid leukemia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
EP0215126B1 (en) * 1985-02-08 1991-07-31 Chugai Seiyaku Kabushiki Kaisha Human granulocyte colony stimulating factor

Also Published As

Publication number Publication date
ES2039209T5 (es) 1996-07-16
EP0230980A2 (en) 1987-08-05
ATE65403T1 (de) 1991-08-15
DE3771509D1 (de) 1991-08-29
EP0230980B2 (en) 1996-03-20
EP0230980B1 (en) 1991-07-24
CA1297004C (en) 1992-03-10
EP0230980A3 (en) 1988-07-27

Similar Documents

Publication Publication Date Title
ES2039209T5 (es) Compuesto farmaceutico que promueve el restablecimiento de la capacidad hemopoyetica.
Li et al. Mesenchymal stem cells: characteristics, function, and application
ES2147553T3 (es) Vectores virales recombinantes para la expresion en unas celulas musculares.
ES2063011T3 (es) Agentes antibacteriales de quinolonas y naftiridinas que contienen un alfa-aminoacido en la cadena lateral del 7-sustituyente.
ES2043897T3 (es) Preparado de combinacion, en especial para el tratamiento de enfermedades de las celulas nerviosas.
ES2063033T3 (es) Empleo de igf-ii en el tratamiento de la enfermedades de los huesos.
ES2116986T3 (es) Composiciones de metal-peptidos y metodos cosmeticos para estimular el crecimiento del cabello.
ES2058291T3 (es) Derivados de piperazinilo de las purinas e isosteros de las mismas como agentes hipoglucemicos.
IT1220979B (it) Capsule contenenti un allergene e procedimento per la loro preparazione
ES2102921T3 (es) Utilizacion de derivados de la hormona estimuladora de los melanocitos de tipo alfa para estimular el crecimiento de los cabellos.
ES2043025T3 (es) Un procedimiento para preparar una composicion farmaceutica que contiene acido 3-(aminopropil)metil-fosfinico como agente terapeutico.
ES2058898T3 (es) Compuesto farmaceutico, util a titulo preventivo o curativo contra los tumores inducidos por los papilomavirus.
ES2055684T3 (es) Un metodo para preparar un agente para el tratamiento de la leucopenia.
BRPI0418157A (pt) terapêutica de tumores alogênicos
ES2053454T3 (es) Composiciones farmaceuticas que contienen peptidos del grupo de la colecistoquinina-ceruleina para la terapia de estados de shock y de insuficiencias respiratorias y cardiocirculatorias.
ES2036530T3 (es) Utilizacion de un factor estimulante de las colonias granulociticas humano para preparar una composicion farmaceutica para el tratamiento de la leucemia mielogena.
EP2687217B1 (en) Enhanced autologous growth factor production and delivery system
IL123642A (en) Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration
ES2066237T3 (es) Procedimiento para producir gamma-interferon humano recombinante sin cisteina carente de metionina en el extremo n-terminal.
BR112021019139A2 (pt) Célula de mamífero manipulada, composição, molécula isolada de dna de fita dupla, dispositivo implantável, cápsula de hidrogel, e, método de tratamento de um paciente com doença de fabry
ES2076981T3 (es) Polipeptido fisiologicamente activo y adn.
Janssen et al. A prospective randomized trial comparing blood-and marrow-derived stem cells for hematopoietic replacement following high-dose chemotherapy
ES2196456T3 (es) Compuestos ciclicos de cinco eslabones en el anillo condensado que llevan un grupo sulfonamida, su uso como medicamentos y composiciones farmaceuticas que los contienen.
AR003974A1 (es) Una nueva proteina mp52 arg humana, un proceso para la produccion y aislacion de la misma y composiciones farmaceuticas que la contienen
ES495459A0 (es) Procedimiento para la obtencion de nuevos carbamatos